Valuing the effect sizes hypothesized in phase 3 trials of targeted therapies in oncology
This abstract was not included in this publication as it was already published. See Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 317P (10.1093/annonc/mdw366.02) - Oxford University Press.
Auteurs principaux: | Reilly, G, Wise, A, Attwood, S, Scudder, C, Love, S |
---|---|
Format: | Conference item |
Publié: |
BioMed Central
2017
|
Documents similaires
-
The changing world of clinical trials 2003-2017: A view from the AspECT trial
par: Reilly, G, et autres
Publié: (2017) -
Leveraging homologous hypotheses for increased efficiency in tumor growth curve testing
par: Alan D. Hutson, et autres
Publié: (2023-11-01) -
Conducting tests of hypotheses: the need for an adequate sample size
par: Mohd. Asraf, Ratnawati, et autres
Publié: (2004) -
Sample size determination for Bayesian ANOVAs with informative hypotheses
par: Qianrao Fu, et autres
Publié: (2022-11-01) -
THz therapy and smoking: facts and hypotheses
par: Svetlana S. Parshina
Publié: (2013-11-01)